Insuficiencia suprarrenal pediátrica

[1] M.-F. Kong and W. Jeffcoate, “Eighty-six cases of Addison’s disease,” Clinical Endocrinology, vol. 41, no. 6, pp. 757–761, 1994.

[2] A. C. Willis, “The prevalence of Addison’s disease in Coventry, UK,” Post graduate Medical Journal, vol. 73, no. 859, pp. 286–288, 1997.

[3] K. Løv°as and E. S. Husebye, “High prevalence and increasing incidence of Addison’s disease in western Norway,” Clinical Endocrinology, vol. 56, no. 6, pp. 787–791, 2002.

[4] R. Perry, O. Kecha, J. Paquette, C. Huot, G. van Vliet, and C. Deal, “Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal, ”The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 6, pp. 3243–3250, 2005.

[5] P. W. Speiser, R. Azziz, L. S. Baskin et al., “Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 9, pp. 4133–4160, 2010.

[6] W. Arlt and B. Allolio, “Adrenal insufficiency,” The Lancet, vol. 361, no. 9372, pp. 1881–1893, 2003.

[7] D. I. Shulman, M. R. Palmert, and S. F. Kemp, “Adrenal insufficiency: Still a cause of morbidity and death in childhood,” Pediatrics, vol. 119, no. 2, pp. e484–e494, 2007.

[8] S. Vallette-Kasic, T. Brue, A.-M. Pulichino et al., “Congenital isolated adrenocorticotropin deficiency: An underestimated cause of neonatal death, explained by TPIT gene mutations,” The Journal of Clinical Endocrinology &Metabolism, vol. 90, no. 3, pp. 1323–1331, 2005.

[9] M.D.Thompson, E. Kalmar, and S. A. Bowden, “Severe hyponatraemia with absence of hyperkalaemia in rapidly progressive Addison’s disease,” BMJ Case Reports, vol. 2015, 2015.

[10] K. Kamoi, T. Tamura, K. Tanaka, M. Ishibashi, and T. Yamaji, “Hyponatremia and osmoregulation of thirst and vasopressin secretion in patients with adrenal insufficiency,” The Journal of Clinical Endocrinology & Metabolism, vol. 77, no. 6, pp. 1584–1588, 1993.

[11] N. El-Farhan, A. Pickett, D. Ducroq et al., “Method-specific serum cortisol responses to the adrenocorticotrophin test: Comparison of gas chromatography-mass spectrometry and five automated immunoassays,” Clinical Endocrinology, vol. 78, no. 5, pp. 673–680, 2013.

[12] M. C.Klose, M. Lange, A. K. Rasmussen et al., “Factors influencing the adrenocorticotropin test: Role of contemporary cortisol assays, body composition, and oral contraceptive agents,” The

Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 4, pp. 1326–1333, 2007.

[13] R. Kazlauskaite, A. T. Evans, C. V. Villabona et al., “Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: A metaanalysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 11, pp. 4245–4253, 2008.

[14] S. R. Rose, R. H. Lustig, S. Burstein, P. Pitukcheewanont, D. C. Broome, and G. A. Burghen, “Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test,” Hormone Research, vol. 52, no. 2, pp. 73–79, 1999.

[15] G. Dickstein and W. Oelkers, “Commentary to the article: Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease [4] (multiple letters),” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 12, pp. 4531–4533, 1998.

[16] M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, and L. Nieman, “Technical details influence the diagnostic accuracy of the 1 ??g ACTH stimulation test,” European Journal of Endocrinology, vol. 162, no. 1, pp. 109–113, 2010.

[17] L. K.Coshway, J. A. Indyk, and S. A. Bowden, “Repeating ACTH Stimulation Test Is Necessary to Diagnose ACTH Deficiency in Neonatal Hypopituitarism With Initial False Negative Result,” Global Pediatric Health, vol. 1, p. 2333794X1456338, 2014.

[18] R. Sirianni, K. S. Rehman, B. R. Carr, C. R. Parker Jr., and W. E. Rainey, “Corticotropin-releasing hormone directly stimulates cortisol and the cortisol biosynthetic pathway in human fetal adrenal cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 1, pp. 279–285, 2005.

[19] R. H. Rao and G. S. Spathis, “Intramuscular glucagon as a provocative stimulus for the assessment of pituitary function: Growth hormone and cortisol responses,” Metabolism, vol. 36, no. 7, pp. 658–663, 1987.

[20] A. Tenenbaum, M. Phillip, and L. De Vries, “The intramuscular glucagon stimulation test does not provide good discrimination between normal and inadequate ACTH reserve when used in the investigation of short healthy children,” Hormone Research in Paediatrics, vol. 82, no. 3, pp. 194–200, 2014.

[21] H. C. Johnstone and T. D. Cheetham, “GH and cortisol response to glucagon administration in short children,” Hormone Research, vol. 62, no. 1, pp. 27–32, 2004.

[22] Y. Simsek, Z. Karaca, F. Tanriverdi, K. Unluhizarci, A. Selcuklu, and F. Kelestimur, “A comparison of low-dose ACTH, glucagon stimulation and insulin tolerance test in patients with pituitary disorders,” Clinical Endocrinology, vol. 82, no. 1, pp. 45–52, 2015.

[23] A. H. Hamrahian, K. C. J. Yuen, M. B. Gordon, K. J. Pulaski- Liebert, J. Bena, and B. M. K. Biller, “Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic–pituitary–adrenal axes in adults: results from a prospective randomized multicenter study,” The Pituitary Society, vol. 19, no. 3, pp. 332–341, 2016.

[24] G. Binder, A. Bosk, M. Gass, M. B. Ranke, and P.H. Heidemann, “Insulin tolerance test causes hypokalaemia and can provoke cardiac arrhythmias,” Hormone Research, vol. 62, no. 2, pp. 84–87, 2004.

[25] T. M. Flad, J. M. Kirby, S. K. Cunningham, and T. J. McKenna, “The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis,” Clinical Endocrinology, vol. 40, no. 5, pp. 603–609, 1994.

[26] B. L. Linder, N. V. Esteban, A. L. Yergey, J. C. Winterer, D. L. Loriaux, and F. Cassorla, “Cortisol production rate in childhood and adolescence,” Journal of Pediatrics, vol. 117, no. 6, pp. 892–896, 1990.

[27] C. J. De Vile and R. Stanhope, “Hydrocortisone replacement therapy in children and adolescents with hypopituitarism,” Clinical Endocrinology, vol. 47, no. 1, pp. 37–41, 1997.

[28] P. M.Mah, R. C. Jenkins, A. Rostami-Hodjegan et al., “Weight related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency,” Clinical Endocrinology, vol. 61, no. 3, pp. 367–375, 2004.